Bioprocess > Overview

Overview

Enabling tomorrow's therapeutics

Downstream processing represents a significant bottleneck in the biopharmaceutical industry. To meet growing demands, a robust and scalable platform is required that can effectively isolate a wide range of biotherapeutics.

Upfront's Rhobust™ universal processing platform enables customers to efficiently recover and purify monoclonal antibodies, therapeutic proteins and other biomolecules direct from blood plasma or bioreactors, under cGMP-compliant conditions, up to commercial scale.